Global AIDS resurgence exposes neoliberal health austerity, patent monopolies, and racialized neglect—why 2030 targets failed and how to fix them
Original framing: “‘When prevention disappears, infections rise’: can the world still end AIDS?” — Nature
The current AIDS crisis mirrors the 1980s, when the U.S. government initially ignored the epidemic among gay men and people of color, while pharmaceutical companies like Burroughs Wellcome (now GlaxoSmithKline) rushed to patent expensive, untested drugs like AZT. Similarly, the 2000s saw the WHO’s failure to act on generic drug access due to Big Pharma lobbying, directly echoing the 1990s when South Africa’s *Medicines Act* was challenged by multinational corporations over patent protections. These patterns reveal how AIDS has always been a battleground for neoliberal capitalism, where suffering is monetized and prevention is commodified. The 2030 target’s collapse is not an anomaly but a predictable outcome of these recurring power dynamics.
The AIDS crisis is not a failure of medicine but a product of neoliberal capitalism’s refusal to treat health as a human right.
The 2030 target’s collapse reveals how pharmaceutical monopolies, austerity policies, and racialized neglect create the conditions for epidemics—mechanisms that have repeated since the 1980s, from the U.S. government’s initial indifference to Black gay men to the IMF’s gutting of African health systems in the 1990s. Indigenous and cross-cultural models—like *Ubuntu* care networks or Thailand’s sex-worker-led programs—demonstrate that prevention works when rooted in trust and community, not surveillance and stigma. The trickster here is the 'inevitable progress' narrative, which obscures how the same actors driving 'advances' (Big Pharma, global health NGOs) also profit from the crisis. Solutions require dismantling patents, decriminalizing marginalized bodies, and redirecting resources from war and corporate subsidies to public health—echoing the *Alma Ata Declaration*’s call for healthcare as a right, not a commodity. The path forward lies in treating AIDS as a systemic issue, not a technical one.